Today's Alert

SPECIAL EARLY ALERT! IMLFF (InMed Pharmaceuticals Inc.) is our New Epic Pick for Tomorrow!

Posted on

Good Evening Traders,

With so many of you asking for us to release our alerts earlier – before the Bell, we have decided to release Tomorrow’s Alert 1 DAY EARLY for Epic Members ONLY!   Check it out below…

IMLFF (InMed Pharmaceuticals Inc.) is our New Epic Pick!
Last Price: .27  |  SEC Filings  |  Latest News

Begin your research at

Today we head back into the wild world of the Medical Marjuana Sector with a company that may truly be head and shoulders above the rest.

After last year’s historic US Election, we now have 9 STATES that have fully legalized Marjuana for recreational use while a MAJORITY of the entire US Population (28 States) now has access to MEDICAL Marjuana.

With the barriers finally coming down on Prohibition and Medical Science now confirming the extraordinary effects of Marjuana, Today’s New Alert may now be in a position to capitalize from this rising trend more than EVER BEFORE!



Dual-listed on the OTCQB and CSE Exchange (IN.V) in Canada, IMLFF is a pre-clinical stage Biopharmaceutical company that specializes in developing therapies through the Research and Development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.

IMLFF is taking a very unique approach to treatment through Canna.bis.   Where most others research the most easily isolated cannabinoid of THC, IMLFF has developed a process and tool to enable research of the disease-fighting effects of ALL 90+ CANNABINOIDS that exist!

Not only is IMLFF’s scientific discovery amazing…it could potentially be REVOLUTIONARY in discovering ALL the treatment, healing, and curing possibilities from every part of the Canna.bis plant!

Already in the pipeline for the company are two therapies to tackle Glaucoma and Epidermolysis Bullosa – a potential market of over $6 BILLION per year!!

So it’s no surprise that IMLFF has attracted Execs from Pharmaceutical & Biotech Powerhouses such as Eli Lilly and GW Pharmaceuticals!  This is a true test of how SERIOUS this company is.

And perhaps that’s why IMLFF currently has what may be…the Perfect Chart.  Let’s take a look.

Like many in the sector, IMLFF has been on a phenomenal run since the Election.

Since reaching highs of .4261, IMLFF’s chart now displays a classic Ascending Triangle Pattern where it sits right above support of our lower trend line and just below the upper trend line resistance.

With so much in the pipeline, could IMLFF stage an epic BREAKOUT of this pattern and move to the Next Level?  See below…

On our side is Technical Analysis site,, who currently gives IMLFF a “BUY” Rating!

InMed Pharmaceuticals (IMLFF) is a clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.

Cannabinoids are a group of active compounds found in marjuana that are responsible for it’s effects on the body and the reason why medical marjuana works to alleviate so many symptom-related ailments from Cancer to inflammation and more.

Canna.bis produces 90+ individual cannabinoids. The most well known are THC and CBD.

What most are unaware of is that the HUMAN BODY naturally produces endo-cannabinoids and has receptors that interact with those from the plant which effect everything from metabolism to pain!

IMLFF is still a relatively small company – but with a single BIG idea:  use biosynthesis to create the cannabinoids found in tiny amounts in naturally grown marjuana.

InMed has developed and patented a technologically advanced process to isolate the active cannabinoids and produce them biosynthetically.

This enables the research of the disease-fighting effects of ALL 90+ Cannabinoids – not just THC and CBD which is what most others are researching!

Advantages of InMed’s Bioinformatics Tool

  • Generates new therapies both quickly and effectively – significant cost and time savings in discovery process.
  • Allows InMed to research pharmacological responses of ALL 90+ cannabinoids.
  • Has already identified multiple therapies including InMed’s INM-750 & INM-085.

The potential competitive advantage here could be ENORMOUS!

To truly understand what IMLFF is all about, you MUST check out this Company Explanation Video + Interview with the CEO courtesy of BNN.


So far IMLFF’s bioinformatics assessment has been used to identify two disease development programs:

  • INM-750 for Epidermolysis Bullosa – An orphan pediatric disease characterized by extremely fragile skin with no current approved therapies.  Potential of $1 BIL/year

    INM-750 targets cannabinoid receptors in the skin to deliver symptomatic relief:

    1) Accelerated wound healing   2) pain & itch reduction   3)  reduce inflammation
    4)  antimicrobial activity  5) may REVERSE the disease

  • INM-085 for Glaucoma – A serious eye disease with a global market of $5 BIL+/year

    INM-085 is a combination of cannabinoids selected to:
    1) Reduce the intraocular pressure in the affected eyes  2)  Provide neuroprotection for the retinal ganglion cells


A century ago, a diabetes diagnosis was basically a death sentence.

Then in the early 1970s, a tiny and innovative biotech company found that it could combine strains of E. coli bacteria with human genes to produce what’s called a “biosynthetic insulin.”

That small company was Genentech who ended up partnering with Eli Lilly to produce biosynthetic insulin,  turning it into a $35 BIL a year industry today!

Eli Lilly is now a $73 billion pharmaceutical giant.

Now, IMLFF is targeting the exact same thing as Genentech within the Canna.bis industry WITH an Eli Lilly executive on board!


GW Pharmaceuticals (GWPH) successfully isolated a particular part of the marjuana plant and brought to market a multiple sclerosis treatment that’s approved for use in dozens of countries.

GW’s success in developing pharmaceutical drugs from marjuana has sent its shares from less than $9 in 2013 to more than $129 today with a market value of more than $2.9 billion!!!

GW Pharma has only identified 14 or so Cannabinoids to develop therapies with and their method of extraction is time consuming and costly.

IMLFF, on the other hand, has a tool that can potentially identify all 90+ Cannabinoids!!

So it’s no wonder why IMLFF’s new Chief Medical Officer jumped ship from GW Pharmaceuticals where he previously served as an Associate Medical Director!

It’s no surprise that so many are calling IMLFF the “Next GW Pharmaceuticals (GWPH)” which trades at $129!  See here and here.

With a potential BREAKOUT Chart, a strong management team, a potentially revolutionary process, and treatments soon to enter Pre-Clinical Trials, there may be NO BETTER TIME to check out IMLFF than right now!

This is why IMLFF may be our BIGGEST Medical Marjuana Alert of the Year!

Make sure you put it on your screen TOMORROW MORNING and Follow on Twitter for Updates + Play-by-Play!


Please read our Full Disclaimer:

This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.  The paying party may own shares and may liquidate them during the promotional period.

PLEASE NOTE WELL: and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice.


You are reading this newsletter because you have subscribed via our Opt-In Signup form on our Website. If you have been subscribed by mistake, you may unsubscribe HERE.

This Newsletter is now owned and operated by Link Media. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our”  refers to Link Media and/or it’s subscriber base. Our website and newsletter are for entertainment purposes only. This newsletter is NOT a source of unbiased information.  Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Gains mentioned in our newsletter and on our website may be based on End of Day or intraday data. The disclaimer is to be read and fully understood before using our site, or joining our email list. Full disclaimer can be read at

We encourage all to read the SEC INVESTOR ALERT before reading our Newsletter.

Release of Liability: Through use of this email and/or website advertisement viewing or using you agree to hold, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by or an offer or solicitation to buy or sell any security.

COMPENSATION: has been compensated fifty thousand dollars cash via bank wire by a third party, Think Ink Marketing for a one day, InMed Pharmaceuticals Inc. advertising services contract. does not own any shares of IMLFF. does not investigate the background of any third party. The third party may have shares and may liquidate it, which may negatively affect the stock price. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. may purchase shares on the open market of any mentioned company following the dissemination of this email. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is collected from public sources only such as the profiled company’s website, news releases, and corporate filings, but has not been verified in any way to ensure the publicly available information is correct. makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Further, has no advance knowledge of any future events of the profiled companies which includes, but is not limited to, news press releases, changes in corporate structure, or changes in share structure.

None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. is compliant with the Can Spam Act of 2003. does not offer such advice or analysis, and further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.

The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements.  Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks an uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results.  Past Performance is based on the security’s previous day closing price and the high of day price during our promotional coverage.

In preparing this publication, has relied upon information supplied by various public sources and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this email and website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. is not responsible for any claims made by the companies advertised herein, nor is responsible for any other promotional firm, its program or its structure.